The Full Wiki

More info on RTI-371

RTI-371: Wikis

Advertisements

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

RTI-371
Systematic (IUPAC) name
3-(4-chlorophenyl)-5-[(1R,2S,3S,5S)-8-methyl-3-(4-methylphenyl)-8-azabicyclo[3.2.1]octan-2-yl]-1,2-oxazole
Identifiers
ATC code  ?
PubChem 11474847
Chemical data
Formula C24H25ClN2O 
Mol. mass 392.920
SMILES eMolecules & PubChem
Therapeutic considerations
Pregnancy cat.  ?
Legal status


3β-(4-methylphenyl)-2β-[3-(4-chlorophenyl)isoxazol-5-yl]tropane (RTI-371) is a phenyltropane derived drug which acts as a potent and selective dopamine reuptake inhibitor in vitro, yet unusually for this class of compound, both RTI-371 and the closely related compound RTI-370 failed to produce locomotor stimulation in mice. In addition to this, in drug substitution tests RTI-370 weakly generalized to cocaine whereas RTI-371 did not generalize at all.

This phenomenon has also been observed for other dopamine reuptake inhibitors from other classes. It may be caused by lack of BBB penetration, or interactions at alternative receptor sites.[1] Recently the second of these hypotheses was suggested for this compound when it was discovered that RTI-371 also acts as a positive allosteric modulator of the hCB1 human cannabinoid receptor.[2]

See also

References

  1. ^ Runyon, SP; Carroll (2006). "Dopamine transporter ligands: recent developments and therapeutic potential". Current topics in medicinal chemistry 6 (17): 1825–43. doi:10.2174/156802606778249775. ISSN 1568-0266. PMID 17017960.  edit
  2. ^ Navarro HA, Howard JL, Pollard GT, Carroll FI. Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter. Br J Pharmacol. 2009 Apr;156(7):1178-84. PMID 19226282
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message